Sun Pharmaceutical Industries has announced the biggest deal ever in Indian pharma, agreeing to buy Organon in a transaction valued at $11.75 billion.
Normally, when a company unveils a debt-funded acquisition of this size, markets get nervous first. Investors worry about borrowing, integration risk and whether management has overpaid.
But that did not happen here.
Shares of Sun Pharmaceutical Industries rose sharply after the announcement, climbing 8.07% to Rs 1,750.65 on the BSE at 10:26 am, suggesting investors largely welcomed the Organon acquisition despite the large price tag.
If you missed it, we reported earlier that the Sun Pharma share price surged after news of the biggest Indian pharma deal broke.
So why did Dalal Street give the move a thumbs up?
FIRST, WHAT IS SUN PHARMA BUYING?
Organon is a global pharmaceutical company with businesses across women’s health, established medicines and biosimilars.
Let’s decode that.
Women’s health includes products linked to fertility and contraception. Established medicines are older brands that still sell steadily and generate cash. Biosimilars are lower-cost alternatives to expensive biologic drugs and are seen as a major future growth area.
Organon sells products in more than 140 countries. That means Sun Pharma is not just buying products. It is buying access, scale and ready-made global reach.
WHY MARKETS SAW VALUE
Investors appear to like that this is not a random diversification move.
The acquisition gives Sun Pharma an immediate presence in women’s health, where Organon already has a strong position. It also strengthens Sun Pharma’s play in biosimilars, a segment many pharma companies want to enter more meaningfully.
Then there is geography. Organon has operations across multiple markets, helping Sun Pharma become less dependent on any one region.
In simple terms, markets seem to see this as buying future growth, not just buying size.
If you missed our earlier coverage, we also explained why the Sun Pharma share price jumped in early trade after the announcement.
SUN PHARMA’S TRACK RECORD
This is a big reason why the reaction was positive.
Sun Pharma has spent years expanding through acquisitions, product buys and strategic deals. Its best-known large transaction was the Ranbaxy takeover in 2014, which came with regulatory and operational issues. Sun Pharma eventually integrated the business and used the scale to strengthen its market position.
It has also acquired specialty assets and rights for products such as Cequa and Odomzo as part of its move beyond plain generics. Sun’s own investor presentation highlighted M&A as a long-term part of its value creation strategy.
That history matters. Markets are usually more comfortable backing a management team that has handled acquisitions before.
YES, THE DEBT QUESTION REMAINS
No one is ignoring the price tag.
Sun Pharma said $2 billion to $2.5 billion of the acquisition will be funded through cash on hand. The remaining $9.25 billion to $9.75 billion will come through committed bank financing.
Yes, that means debt will rise.
But investors seem reassured by the fact that Organon is a profitable operating business with revenue and cash generation, not a speculative bet.
Sun Pharma has also said the combined entity could generate around $2.5 billion in free cash flow before financing.
Free cash flow simply means money left after running the business and necessary spending. That is the money that can be used to repay loans.
WHAT INVESTORS SHOULD TRACK
The market reaction suggests investors are focused on what this deal can deliver over time.
Sun Pharma becomes bigger globally almost immediately. It adds a ready business in women’s health. It gets a stronger biosimilars platform without spending years building one from scratch.
Investors may also be betting that Sun Pharma can improve efficiency and unlock more value from Organon over time, something it has managed with past deals.
That likely explains the upbeat early response in the Sun Pharma share price.
Of course, announcement day is the easy part.
The deal still needs approvals. Then comes integration, where many big acquisitions become difficult. Different teams, systems and geographies need to work smoothly together.
There is also the debt factor. If growth slows or cash flows disappoint, investor enthusiasm can fade quickly.
So yes, the Street liked the news. But it will now watch execution closely.
WHAT’S THE REAL TAKEAWAY?
Markets did not cheer this deal only because it was big.
They cheered because Sun Pharma is seen as a company with the scale, balance sheet and operating record to attempt something this ambitious.
Right now, Dalal Street seems willing to trust that bet. The next few quarters will decide whether that confidence was right.
